PHASE 1/2 STUDY USING ENB-003, A FIRST-IN-CLASS SELECTIVE ETBRI, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED REFRACTORY SOLID TUMORS

被引：1
|
作者：
Jamal, Sumayah [1 ]
Nagrial, Adnan [2 ]
Joshua, Anthony [3 ]
Eek, Richard [4 ]
Jamal, Sumayah [1 ]
机构：
[1] ENB Therapeut Inc, New York, NY USA
[2] Blacktown Canc & Haematol, Blacktown, NSW, Australia
[3] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[4] Border Med Oncol Res Unit, Albury, NSW, Australia
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0803
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
803
引用
收藏
页码：A480 / A481
页数：2
相关论文
共 50 条
  • [31] Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)
    Shapiro, Geoffrey
    Wesolowski, Robert
    Middleton, Mark
    Devoe, Craig
    Constantinidou, Anastasia
    Papadatos-Pastos, Dionysis
    Fricano, Marjorie
    Zhang, Yanqiong
    Karan, Sharon
    Pollard, John
    Penney, Marina
    Asmal, Mohammed
    Renshaw, F. Gary
    Fields, Scott Z.
    Yap, Timothy A.
    CANCER RESEARCH, 2016, 76
  • [32] A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors
    Yarchoan, Mark
    Powderly, John D.
    Bastos, Bruno R.
    Karasic, Thomas Benjamin
    Crysler, Oxana V.
    Munster, Pamela N.
    McKean, Meredith
    Emens, Leisha A.
    Saenger, Yvonne M.
    Ged, Yasser
    Stagg, Robert
    Goutopoulos, Andreas
    Moon, Anne
    Jenkins, Yonchu
    Prasit, Peppi
    Dubensky, Thomas Walter
    Whiting, Sam H.
    Ulahannan, Susanna Varkey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
    Plummer, Elizabeth R.
    Dean, Emma Jane
    Evans, T. R. Jeffry
    Greystoke, Alastair
    Herbschleb, Karin
    Ranson, Malcolm
    Brown, Jennifer
    Zhang, Yanqiong
    Karan, Sharon
    Pollard, John
    Penney, Marina S.
    Asmal, Mohammed
    Fields, Scott Z.
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
    Perets, R.
    Stemmer, S. M.
    Geva, R.
    Golan, T.
    Fakih, M.
    Cohen, J. E.
    Lieu, C.
    Jin, Z.
    Lorusso, P.
    Friedman, I.
    Hakim, M.
    Ziv, D. Haves
    Hashmueli, S.
    Mandel, I.
    Ben Moshe, T.
    Crawford, N.
    Abbadessa, G.
    Perez, R.
    Wu, M.
    Borad, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S675 - S675
  • [35] A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.
    El-Khoueiry, Anthony B.
    Thomas, Jacob Stephen
    Olszanski, Anthony J.
    Azad, Nilofer Saba
    Whalen, Giles Francis
    Hanna, Diana L.
    Ingham, Matthew
    Mahmood, Syed
    Bender, Lewis H.
    Walters, Ian B.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
    Lorens, James
    Arce-Lara, Carlos Eduardo
    Arriola, Edurne
    Brunsvig, Paal
    Costa, Enric Carcereny
    Domine, Manuel
    Dragnev, Konstantin H.
    Felip, Enriqueta
    Campelo, Rosario Garcia
    Krebs, Matthew
    Aix, Santiago Ponce
    Spicer, James F.
    Perez, Jose Manuel Trigo
    Vinolas, Nuria
    Holt, Robert J.
    Brown, Anthony
    Chisamore, Michael Jon
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors
    Schram, Alison M.
    Nagash, Abdul Rafeh
    Haura, Eric B.
    Riess, Jonathan W.
    Ulahannan, Susanna V.
    Ou, Sai-Hong I.
    Capasso, Anna
    Munster, Pamela N.
    Cheng, Michael L.
    Gustafson, W. Clay
    Bitman, Bojena
    Kar, Sumit
    Wang, Zhican
    Tao, Lin
    Meyerowitz, Justin G.
    Burns, Howard A.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [38] A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors
    Laurie, Scott Andrew
    Jonker, Derek J.
    Edenfield, William Jeffery
    Stephenson, Joe
    Keller, Deborah
    Hitron, Matthew
    Li, Wei
    Li, Youzhi
    Gada, Keyur
    Gao, Yuan
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
    Pauff, James Michael
    Papadopoulos, Kyriakos P.
    Janku, Filip
    Turk, Anita Ahmed
    Goyal, Lipika
    Shroff, Rachna T.
    Shimizu, Toshio
    Ikeda, Masafumi
    Azad, Nilofer Saba
    Cleary, James M.
    Peters, Mary Linton Bounetheau
    Borad, Mitesh J.
    Jaeckle, Kurt A.
    Kizilbash, Sani Haider
    Tupper, Rebecca
    Furin, Carrie E.
    Hanley, Matthew P.
    Hill, Elizabeth Goodwin
    Xu Xiaojian
    Harding, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [40] Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors
    Saeed, Anwaar
    Bashir, Babar
    Luke, Jason J.
    Chantre, Reuven
    Amsili, Shira
    Tabakman, Rinat
    Shwartz, Yaffa
    Foley-Comer, Adam
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345